BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eylea aflibercept ophthalmic solution: Additional Phase III data

A pooled analysis of the double-blind, international Phase III VIEW 1 and 2 trials in 1,217 and 1,240 patients, respectively, showed that 2 mg Eylea every 8 weeks led to gains in visual acuity that were similar to that of 0.5 mg Lucentis ranibizumab every 4 weeks, but with an average of about 5 fewer injections, at week 96. Specifically, patients receiving Eylea had an improvement of 7.6 letters in visual acuity from baseline with an average of 11.2 injections over 96 weeks. Patients receiving...

Read the full 415 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >